RedHill Biopharma (RDHL) Further Analysis of Phase 2/3 Data Shows 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

Go back to RedHill Biopharma (RDHL) Further Analysis of Phase 2/3 Data Shows 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

October 4, 2021 8:16 AM EDT

62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm (7 deaths in the 117-patient opaganib arm vs. 21 deaths in the 134-patient placebo arm; nominal p-value=0.019)

21% statistically significant efficacy benefit with opaganib in reaching room air by Day 14, the study primary endpoint (77% of opaganib patients vs 63.5% on placebo; nominal p-value=0.033)

A median four days earlier hospital discharge for opaganib-treated patients vs. placebo (10 days for opaganib arm vs. 14 days for placebo) a cumulative saving of 524 days of hospitalization across the group by Day 42 (nominal... More